The estimated Net Worth of Gregory Ian Frost is at least $19.2 Миллион dollars as of 28 May 2015. Gregory Frost owns over 200,000 units of Halozyme Therapeutics stock worth over $17,817,000 and over the last 17 years Gregory sold HALO stock worth over $1,409,076.
Gregory has made over 34 trades of the Halozyme Therapeutics stock since 2007, according to the Form 4 filled with the SEC. Most recently Gregory exercised 200,000 units of HALO stock worth $4,554,000 on 28 May 2015.
The largest trade Gregory's ever made was exercising 639,902 units of Halozyme Therapeutics stock on 19 March 2008 worth over $275,158. On average, Gregory trades about 49,580 units every 68 days since 2007. As of 28 May 2015 Gregory still owns at least 300,000 units of Halozyme Therapeutics stock.
You can see the complete history of Gregory Frost stock trades at the bottom of the page.
Over the last 17 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay и Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: